Corporate Presentation at J.P. Morgan Healthcare Conference - Alkermes plc will present its corporate presentation at the J.P. Morgan Healthcare Conference on January 15, 2025, including expectations for cash and investments for the year ended December 31, 2024 [5] - The corporate presentation is furnished as Exhibit 99.1 and incorporated by reference in Item 7.01 [6] - Alkermes plc's corporate presentation is listed as Exhibit 99.1 in the Exhibit Index [9] Form 8-K Filing Information - The information in the Form 8-K, including Items 2.02 and 7.01, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 [7]

DUBLIN, Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.7th Annual Evercore ISI HealthCONx ConferenceDate/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m. ET (3:25 p.m. GMT)Piper Sandler 36th Annual Healthcare ConferenceDate/Time: Wednesday, Dec. 4, 2024 at 4:00 p.m. ET (9:00 p.m. GMT)The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.About Alkermes plcAlkermes ...

DUBLIN, Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences.Stifel Healthcare ConferenceDate/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT)Jefferies London Healthcare ConferenceDate/Time: Tuesday, Nov. 19, 2024 at 8:00 a.m. ET (1:00 p.m. GMT)The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.About Alkermes plcAlkermes plc is a global biopharmace ...

Alkermes plc (ALKS) reported adjusted earnings from continuing operations of 73 cents per share for thirdquarter 2024, which missed the Zacks Consensus Estimate of 78 cents. The company had reported adjusted earnings of 87 cents per share in the year-ago quarter. ALKS' total revenues of $378.1 million declined 0.7% from the year-ago quarter's level owing to lower manufacturing and royalty revenues. The top line, also, missed the Zacks Consensus Estimate of $386 million. Shares of Alkermes were down 3.6% on ...

Alkermes plc (NASDAQ:ALKS) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Richard Pops - CEO Todd Nichols - Chief Commercial Officer Blair Jackson - Chief Operating Officer. Conference Call Participants Joseph Thome - TD Cowen Umer Raffat - Evercore Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler Joel Beatty - Baird Uy Ear - Mizuho Securities Jessica Fy ...

Alkermes (ALKS) reported $378.14 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 0.7%. EPS of $0.73 for the same period compares to $0.64 a year ago.The reported revenue represents a surprise of -2.06% over the Zacks Consensus Estimate of $386.09 million. With the consensus EPS estimate being $0.78, the EPS surprise was -6.41%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35299 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I ...

Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.41%. A quarter ago, it was expected that this drugmaker would post earnings of $0.73 per share when it actually produced earnings of $0.72, delivering a surprise of -1.37%.Over the last four quarters, the company has s ...

Exhibit 99.1 1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2024 Financial Results — Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 — — Company Reiterates 2024 Financial Expectations — DUBLIN, Oct. 24, 2024 — ...

— Third Quarter Revenues of $378.1 Million —— Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year —— GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 —— Company Reiterates 2024 Financial Expectations —DUBLIN, Oct. 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2024."Our third quarter financial results reflect strong year-over-year growth ...